Hematology Review: Platelet Disorders

<p>Tissue plasminogen activator (TPA) (B)</p> Signup and view all the answers

<p>Factor X (C)</p> Signup and view all the answers

<p>Protein C and Protein S (C)</p> Signup and view all the answers

<p>Higher than normal levels of nitric oxide (NO) (C)</p> Signup and view all the answers

<p>Aspirin ingestion (A)</p> Signup and view all the answers

<p>Glanzmann thrombasthenia (D)</p> Signup and view all the answers

<p>Storage pool disease (B)</p> Signup and view all the answers

<p>Endothelial cell (D)</p> Signup and view all the answers

<p>Tissue factor (C)</p> Signup and view all the answers

<p>Fibrinogen (A)</p> Signup and view all the answers

<p>Abnormal platelet response to ristocetin (D)</p> Signup and view all the answers

<p>To carboxylate the factors to allow for the prothrombin group factors (A)</p> Signup and view all the answers

<p>Altered expression of phospholipids on the platelet membrane (D)</p> Signup and view all the answers

<p>Acute ITP (A)</p> Signup and view all the answers

<p>Abnormal bone formation, including hypoplasia of the forearms (C)</p> Signup and view all the answers

<p>Anagrelide (B)</p> Signup and view all the answers

<p>Mucosal bleeding (D)</p> Signup and view all the answers

<p>The platelet membrane protein to which it is bound (C)</p> Signup and view all the answers

<p>Thrombocytopenia-absent radius syndrome (C)</p> Signup and view all the answers

<p>The mother has an autoimmune antibody to her own platelets, which crosses the placenta and reacts with the infant’s platelets (B)</p> Signup and view all the answers

<p>Atypical HUS (B)</p> Signup and view all the answers

<p>Factor XIII (B)</p> Signup and view all the answers

<p>Direct binding (B)</p> Signup and view all the answers

<p>Autoimmune destruction of platelets (A)</p> Signup and view all the answers

<p>Antithrombin (AT) (C), Tissue Factor Pathway Inhibitor (TFPI) (D)</p> Signup and view all the answers

<p>May-Hegglin anomaly (D)</p> Signup and view all the answers

A bleeding disorder caused by a defect in GP IIb/IIIa, leading to impaired platelet aggregation.

A blood glycoprotein essential for platelet adhesion and aggregation.

A laboratory test used to evaluate platelet function in regards to VWF.

A hereditary blood disorder characterized by large platelets and impaired aggregation.

The process of producing thrombin, crucial for blood clotting.

Essential for the carboxylation of prothrombin group factors which allows them to function properly.

Triggered by tissue factor leading to the beginning of the coagulation pathway.

A condition where platelets have decreased granules, affecting their function.

Drugs that inhibit platelet aggregation by targeting glycoprotein IIb/IIIa.

Most coagulation factors are synthesized in the liver.

Thrombin activates Factor XIII, stabilizing the fibrin clot.

An autosomal dominant disorder associated with decreased platelet production.

Inhibitors like antithrombin (AT) and tissue factor pathway inhibitor (TFPI) control thrombin generation.

Process where calcium ions attach to specific proteins in blood, aiding in coagulation.

A peptide released during prothrombin proteolysis, indicative of thrombin generation.

A complex that activates Factor X in the coagulation cascade, crucial for thrombin generation.

A protein that promotes fibrinolysis by converting plasminogen to plasmin.

Antibodies that impair platelet aggregation by blocking receptors on platelets.

A protein that mediates platelet adhesion and stabilizes factor VIII in the blood.

A potent vasoconstrictor and promoter of platelet aggregation, inhibited by aspirin.

Decreased platelet function often due to paraproteins or uremia.

A protein critical for the development of NAIT (Neonatal alloimmune thrombocytopenia).

A condition characterized by a sudden decrease in platelet count, often resulting in bleeding complications.

A condition where there is an abnormally low platelet count, which can lead to bleeding disorders.

A drug that reduces platelet count by inhibiting the maturation of megakaryocytes.

A condition where maternal antibodies attack the infant's platelets, leading to low counts.

Hemolytic uremic syndrome characterized by diarrhea caused by certain bacterial infections, like Shigella.

An anticomplement agent used as first-line therapy in atypical hemolytic uremic syndrome (aHUS).

A condition with an excessively high platelet count that is often self-correcting.